Nasdaq

Luminex Files for Emergency Use Authorization for Expanded NxTAG Respiratory Panel Test Including SARS-CoV-2

AUSTIN, Texas, July 22, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has submitted an EUA request to the FDA for a new expanded version of its NxTAG® Respiratory ...
Business Insider

Luminex Receives FDA Emergency Use Authorization for NxTAG® CoV Extended Panel to Detect the SARS-CoV-2 Virus that Causes COVID-19 Disease

AUSTIN, Texas, March 27, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its ...
News Medical

Luminex's NxTAG Respiratory Pathogen Panel receives CE-IVD marking

Luminex Corporation (NASDAQ: LMNX) today announced that it has received CE-IVD marking for its NxTAG® Respiratory Pathogen Panel. The Panel detects 21 clinically-relevant viral and bacterial ...
News Medical

Luminex's NxTAG Respiratory Pathogen Panel obtains FDA clearance

Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for its NxTAG® Respiratory Pathogen Panel that detects 20 clinically relevant viral and bacterial respiratory ...
Pharmabiz

Luminex seeks US FDA approval for NxTAG respiratory pathogen panel

Luminex Corporation has submitted a 510(k) application to the FDA for the company's NxTAG respiratory pathogen panel. This panel is the only respiratory assay that will easily enable laboratories to ...
Pharmabiz

Luminex gets US FDA Emergency Use Authorization and CE Mark for expanded NxTAG Respiratory Panel Test Including SARS-CoV-2

Luminex Corporation announced that it has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a new expanded version of its NxTAG Respiratory Pathogen Panel ...